Tag: Alkermes’ Lybalvi

FDA, Regulations

FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder

June 2, 2021

Via: Pharma Times

Lybalvi (olanzapine and samidorphan) has been authorised as maintenance monotherapy of adults with schizophrenia or bipolar I disorder, for the acute treatment of manic or mixed episodes and as monotherapy or an adjunct to lithium or valproate. In clinical trials, […]